Onco Actu - Spécial AACR 3

Lire aussi l'autre billet du jour

	5.9 AACR
At NCI, Supporting the Best Science [National Cancer Institute] Doug Lowy: Yesterday, at the annual meeting of the American Association for Cancer Research (AACR), I had my first chance to speak directly to the research community in my new role as NCI Acting Director.
AACR 2015: Report from Day 4 [CRI] Day 4 of the annual meeting of the American Association for Cancer Research (AACR) seemed to be all about adoptive cell therapy.
	5.9.1 AACR - sein
Olaparib–Carboplatin Combination Showed Early Signs of Clinical Activity Against Ovarian and Triple-negative Breast Cancers [AACR] The order in which olaparib (Lynparza) and carboplatin chemotherapy were administered to patients with recurrent women’s cancers did not significantly alter the side effects experienced by the patients, and the combination therapy showed preliminary signs of clinical activity in these patients, according to data from a phase I clinical trial.
Olaparib and Investigational PI3K Inhibitor BKM120 Combination Active Against Ovarian and Breast Cancer Subtypes [AACR] In the olaparib/BKM120 dose escalation phase of the clinical trial, Matulonis and colleagues have enrolled 46 patients, 12 with breast cancer and 34 with ovarian cancer. Among these patients, 35 were known to have germline BRCA gene mutations.
	5.9.3 AACR - mélanome
Immunotherapy drug combination shows promise for advanced melanoma patients [Cancer Research UK] Using two antibodies together will make an important difference to the treatment of melanoma, and potentially other cancers too, although the side effects can also be serious.
	5.9.4 AACR - poumon
ARIAD Announces Results of Preclinical Studies on Brigatinib at the American Association for Cancer Research Annual Meeting [ARIAD] Brigatinib is in development for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell lung cancer (NSCLC), who are resistant to crizotinib.
	5.9.5 AACR - CAR-T
Juno's CAR-T contender comes through in another Phase I leukemia study [FierceBiotech] Juno's lead CAR-T asset is JCAR015, an FDA breakthrough-designated ALL treatment, and the biotech is also running trials on the blood cancer treatment JCAR014.
Juno Therapeutics' CAR T Cell Product Candidate JCAR017 Continues to Demonstrate Encouraging Outcomes in Pediatric Patients With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia [Juno Therapeutics] "Given the impressive clinical results with this defined cell product candidate, we are encouraged to begin testing of JCAR017 in adult patients with B cell malignancies, including non-Hodgkin lymphoma, later this year."
	5.9.6 AACR - prostate
Subgroup of Men With Metastatic Prostate Cancer Responded to Olaparib Treatment [AACR] “These are potentially the first clinical data supporting molecular stratification of treatment in prostate cancer, and we are testing this idea in the second stage of the TOPARP trial, TOPARP-B.”
Hope for prostate cancer patients with drug meant for women [The Telegraph] Of a group of 49 men with treatment-resistant, advanced prostate cancer, 16 patients (32.7%) showed a clinical response to olaparib.
AstraZeneca drug Lynparza shows promise in prostate cancer trial [Reuters] AstraZeneca has flagged olaparib as a potential $2-billion-a-year seller, based on ongoing Phase III studies in ovarian, breast, gastric and pancreatic cancers. The latest Phase II prostate findings would represent further upside.
	5.9.7 AACR - divers
New PARP Inhibitor Combo Shows Early Promise for Cancer Patients With and Without BRCA Mutations [AACR] Yap also explained that the ComPAKT clinical trial is, to the best of his knowledge, the first phase I clinical trial using a combination of targeted agents to implement an intrapatient dose-escalation design.
ImmuneXcite Enlists Body's First Defender for Immune Attack on Cancer [Xconomy] While most immune-based cancer treatments currently on or nearing the market focus on enlisting so-called T-cells, ImmuneXcite uses a molecule from a fungus to help coax neutrophils—an aggressive, invader-killing type of cell—into the fray as well.
Metformin Use May Not Improve Pancreatic Cancer Survival [AACR] The median survival for patients who did not use metformin was 308 days, compared with 292 days for patients with various metformin exposures, which was not statistically different. The longest survival, for 818 days, occurred in patients who started taking metformin more than 30 days after PDAC diagnosis.
HPV Vaccine Provides Protection at Multiple Sites, Even Among Some Previously Exposed [AACR] “HPV is a local infection that can separately infect the cervical, anal, or oral sites where it can occasionally lead to cancer. This study demonstrates that the HPV16/18 vaccine provides protection at all three sites, particularly among women without evidence of HPV exposure prior to vaccination,”
Mayo Clinic Researchers Identify Methylated DNA Markers That May One Day Lead To Noninvasive Whole Body Cancer Screening [Mayo Clinic] “DNA methylation may be a way to fingerprint not only the tissues themselves, but also the different types of cancer that might arise in those tissues,” Dr. Kisiel says.
Circadian Responses to Chemo [The Scientist] After exposure to curcumin, rat cancer cell populations undergo a daily cycle of cell death.
Vitamin supplements can increase risk of cancer and heart disease [The Guardian] “We are not sure why this is happening at the molecular level but evidence shows that people who take more dietary supplements than needed tend to have a higher risk of developing cancer.”